Related Experiment Video
Updated: Jan 28, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
MicroRNA‑466 inhibits cell proliferation and invasion in osteosarcoma by directly targeting insulin receptor
Yongning Sun1, Jingzhen Zhou2, Lina Shi1
1Department of Clinical Laboratory, Ningbo No. 6 Hospital, Ningbo, Zhejiang 315040, P.R. China.
Abstract:
Accumulating evidence has demonstrated that microRNAs (miRNAs) are frequently dysregulated in osteosarcoma (OS), and the aberrant expression of miRNAs is associated with OS initiation and progression. Previous studies demonstrated that miRNA‑466 (miR‑466) is dysregulated, and serves important roles in various types of human cancer. However, the role of miR‑466 in the formation and progression of OS remains unclear. In the present study, the expression level of miR‑466 was identified to be markedly downregulated in OS tissues and cell lines. Additionally, miR‑466 overexpression inhibited the proliferative and invasive abilities of OS cells. In the present study, bioinformatics analyses and luciferase assays were employed to show that miR‑466 was able to directly target the 3'‑untranslated region of insulin receptor substrate 1 (IRS1) gene, negatively regulating the mRNA and the protein expression levels of IRS1 in OS cells. Furthermore, IRS1 was upregulated in OS tissues, and the increased expression level of IRS1 exhibited an inverse correlation with the expression level of miR‑466. Furthermore, IRS1 overexpression was able to partially reverse the suppressive effects of miR‑466 overexpression in OS cells. To the best of the authors' knowledge, the present study is the first to suggest that miR‑466 is downregulated in OS and inhibits the progression of OS by directly targeting IRS1. The present results suggested that miR‑466 may represent a novel potential therapeutic target for the treatment of patients with OS.
Insights
MicroRNA-466 (miR-466) is downregulated in osteosarcoma (OS), inhibiting cancer progression. Overexpressing miR-466 suppresses tumor growth and invasion by targeting insulin receptor substrate 1 (IRS1).
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are crucial regulators of gene expression frequently dysregulated in human cancers.
- Aberrant miRNA expression is implicated in the initiation and progression of osteosarcoma (OS).
- The specific role of microRNA-466 (miR-466) in OS pathogenesis was previously unclear.
Purpose of the Study:
- To investigate the expression and function of miR-466 in osteosarcoma.
- To identify the molecular targets of miR-466 in OS.
- To evaluate the therapeutic potential of miR-466 in OS treatment.
Main Methods:
- Quantitative real-time PCR to assess miR-466 expression in OS tissues and cell lines.
- In vitro assays (proliferation, invasion) to evaluate the functional role of miR-466.
- Bioinformatics analysis and luciferase reporter assays to confirm direct targeting of IRS1 by miR-466.
- Western blotting and immunohistochemistry to analyze IRS1 protein levels.
Main Results:
- miR-466 expression was significantly downregulated in OS tissues and cell lines compared to normal controls.
- Overexpression of miR-466 inhibited OS cell proliferation and invasion.
- miR-466 directly targets the 3'-untranslated region of the insulin receptor substrate 1 (IRS1) gene.
- IRS1 expression was upregulated in OS tissues and inversely correlated with miR-466 levels.
- IRS1 overexpression partially rescued the inhibitory effects of miR-466 on OS cell progression.
Conclusions:
- miR-466 acts as a tumor suppressor in osteosarcoma by downregulating IRS1.
- The miR-466/IRS1 axis plays a significant role in OS progression.
- miR-466 represents a potential novel therapeutic target for osteosarcoma treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Insulin: The Receptor and Signaling Pathways
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Internal Receptors

